AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Stock Forecast

Stock Price Forecast

The 4 analysts that cover AbCellera Biologics stock have a consensus rating of "Strong Buy" and an average price target of $7.75, which forecasts a 125.29% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $10.

Price Target: $7.75 (+125.29%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$4.00	$7.75	$10	$10
Change	+16.28%	+125.29%	+190.70%	+190.70%

* Price targets were last updated on Nov 7, 2025.

Analyst Ratings

The average analyst rating for AbCellera Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	2	2	2	2	2	2
Buy	1	1	1	1	1	1
Hold	2	2	2	2	2	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	5	5	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Faisal Khurshid Leerink Partners	Leerink Partners	Buy → Hold Downgrades $4	Buy → Hold	Downgrades	$4	+16.28%	Nov 7, 2025
Stephen Willey Stifel	Stifel	Strong Buy Maintains $8 → $7	Strong Buy	Maintains	$8 → $7	+103.49%	Aug 8, 2025
Scott Schoenhaus Keybanc	Keybanc	Buy Maintains $5 → $10	Buy	Maintains	$5 → $10	+190.70%	Jul 14, 2025
Faisal Khurshid Leerink Partners	Leerink Partners	Buy Initiates $5	Buy	Initiates	$5	+45.35%	Jul 7, 2025
Robyn Karnauskas Truist Securities	Truist Securities	Strong Buy Maintains $28 → $10	Strong Buy	Maintains	$28 → $10	+190.70%	May 16, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

30.49M

Decreased by -59.42%

from 75.13M

Revenue Next Year

37.79M

Increased by 23.96%

from 30.49M

EPS This Year

-0.77

from -0.49

EPS Next Year

-0.82

from -0.77

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	375.20M	485.42M	38.03M	28.83M	75.13M	30.49M	37.79M
Revenue Growth	60.92%	29.38%	-92.17%	-24.17%	160.56%	-59.42%	23.96%
EPS	0.48	0.50	-0.51	-0.55	-0.49	-0.77	-0.82
EPS Growth	6.21%	4.17%	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	9	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030
High	50.4M	70.4M
Avg	30.5M	37.8M
Low	19.5M	25.0M

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030
High	-32.9%	130.7%
Avg	-59.4%	24.0%
Low	-74.0%	-18.0%

EPS Forecast

EPS	2026	2027	2028	2029	2030
High	-0.63	-0.63
Avg	-0.77	-0.82
Low	-0.94	-0.94

EPS Growth

EPS Growth	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.